Skip to main content
Publicerad: 2020-04-29 14:22 | Uppdaterad: 2020-04-29 14:22

CLINTEC-forskare i nytt projekt som finansieras av Europeiska Commissionens Horizon2020 WIDESPREAD-programme

Pauliina Damdimopoulou, Fredrik Lanner och Ganesh Acharya från Karolinska Institutet kommer att arbeta tillsammans med Tartu Universitet (Prof Andres Salumets, koordinator) och University of Maastricht (Prof Masoud Zamaniesteki) i 3 år för att öka kunskaps- och kompetensbyte, innovation och diskussion kring nya teknologier inom reproduktionsmedicin med kvinnan i fokus.

Projektet finansieras av Europeiska Commissionens Horizon2020 WIDESPREAD-programme med 900 000 EURO.

Mer om projektet ERIN: Ethically Responsible Innovations in Reproductive Medicine

Abstract

ERIN project was initiated to spread the academic excellence to University of Tartu (UT) in Estonia as representative of the Widening country, by enhancing networking activities with internationally-leading counterparts, Karolinska Institute (Sweden) and Maastricht University Medical Centre (The Netherlands).

The consortium increases the scientific, innovation and clinical superbness of UT and its partners, by raising the R&I profiles, and the proficiency to identify, explore and resolve the ethical challenges in female reproductive medicine. We deal with the most intimate aspects of human life, by medically assisting conception, by carrying out a genetic analysis of an embryo or fetus to have a healthy baby, and by preserving fertility in women whose fertility is at risk. In the era of rapidly progressing technologies, novel solutions emerge fasten than the conclusive clinical evidence is collected and ethical challenges are addressed. Reproductive medicine is also often unsatisfactorily publicly supported, creating an inequality in access for the most vulnerable category of the patients, women waiting for childbirth. This is why reproductive medicine, covering human life from fertilization till birth, requires special attention to tackle all possible ethical concerns, risks and vulnerabilities, and involving all stakeholders, from individual patients to broad community.

By addressing these challenges, we aim to bring more ethically responsible innovations into clinic that do not harm the interests of the various stakeholders, are evidence-based, cost-effective and therefore could be implemented in a sustainable way to ensure that these novel solutions become widely accessible. As an outcome, ERIN improves the responsible innovation practices, establish ethical system in R&I, expands knowledge and innovation capacity of the UT, and improves proficiency of all partners to facilitate the equity of access to research advances in reproductive medicine.

Contact